ProShare Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-15,422
| Closed | -$631K | – | 2140 |
|
|
2024
Q2 | $631K | Sell |
15,422
-3,716
| -19% | -$152K | ﹤0.01% | 867 |
|
|
2024
Q1 | $809K | Buy |
19,138
+41
| +0.2% | +$1.73K | ﹤0.01% | 855 |
|
|
2023
Q4 | $810K | Buy |
+19,097
| New | +$810K | ﹤0.01% | 814 |
|
|
2023
Q3 | – | Sell |
-8,048
| Closed | -$256K | – | 1875 |
|
|
2023
Q2 | $256K | Buy |
+8,048
| New | +$256K | ﹤0.01% | 1379 |
|
|
2023
Q1 | – | Sell |
-7,372
| Closed | -$233K | – | 1930 |
|
|
2022
Q4 | $233K | Buy |
+7,372
| New | +$233K | ﹤0.01% | 1388 |
|
|
2022
Q2 | – | Sell |
-7,642
| Closed | -$268K | – | 2194 |
|
|
2022
Q1 | $268K | Sell |
7,642
-1,259
| -14% | -$44.2K | ﹤0.01% | 1701 |
|
|
2021
Q4 | $289K | Buy |
+8,901
| New | +$289K | ﹤0.01% | 1815 |
|
|
2021
Q3 | – | Sell |
-9,148
| Closed | -$234K | – | 2316 |
|
|
2021
Q2 | $234K | Buy |
+9,148
| New | +$234K | ﹤0.01% | 2050 |
|